Home › Funds › Soleus Capital Management, L.P. › NRIX

Soleus Capital Management, L.P. position in NRIX

NURIX THERAPEUTICS INC · Health Care

Soleus Capital Management, L.P. reported holding 1,465,163 shares of NRIX (NURIX THERAPEUTICS INC) in its Q2 2026 13F filing — a position valued at US$35.5M, representing 1.22% of its reported portfolio and ranking #24 among its reported holdings. Soleus Capital Management, L.P. has disclosed NRIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

Latest position (Q2 2026)1.47M sh
Reported value held$35.54M
Portfolio Weight1.22%
First reportedQ3 2023
Last changeAdd
Updated2026-10-24

Last updated: 2026-10-24 · Source: SEC EDGAR Form 13F-HR

How Soleus Capital Management, L.P.'s NRIX position evolved

Soleus Capital Management, L.P. first disclosed a stake in NRIX in Q3 2023 at 814,000 shares (US$6.4M). The position peaked in Q2 2024 at 2,055,916 shares, worth US$42.9M. Across 12 filings, Soleus Capital Management, L.P. increased the stake 5 time(s), trimmed it 4 time(s) and left it unchanged 2 time(s). The most recent filing (Q2 2026) shows 1,465,163 shares valued at US$35.5M — an increase of 527,000 shares quarter over quarter.. Notable position changes include a 680% increase in Q1 2024 (shares rose 42% over the following quarter), a 84% increase in Q2 2024 (shares rose 8% over the following quarter), a 97% increase in Q4 2024 (shares fell 37% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 814.00K $6.40M New
Q4 2023 143.00K $1.48M Reduce
Q1 2024 1.11M $16.39M Add
Q2 2024 2.06M $42.91M Add
Q3 2024 1.07M $23.95M Reduce
Q4 2024 2.10M $39.62M Add
Q1 2025 2.42M $28.78M Add
Q2 2025 2.42M $27.60M Hold
Q3 2025 2.42M $22.39M Hold
Q4 2025 1.22M $23.13M Reduce
Q1 2026 938.16K $14.54M Reduce
Q2 2026 1.47M $35.54M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About NRIX and 13F data

NRIX (NURIX THERAPEUTICS INC) is a Health Care company. 46 other funds we track also report a position in NRIX — the largest reported positions include Vestal Point Capital, LP (US$195.3M), Deep Track Capital, LP (US$187.7M), Rubric Capital Management LP (US$175.3M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding NRIX

All NRIX fund holders →

FAQ

How long has Soleus Capital Management, L.P. held NRIX?

Soleus Capital Management, L.P. has disclosed NRIX holdings in 12 of the last 12 reported quarters, going back to Q3 2023.

What is Soleus Capital Management, L.P.'s current position in NRIX?

As of Q2 2026, Soleus Capital Management, L.P. holds 1.47M shares of NRIX (NURIX THERAPEUTICS INC), valued at $35.54M, representing 1.22% of its reported portfolio and ranking #24.

Has Soleus Capital Management, L.P. been buying or selling NRIX?

In the latest 13F filing (Q2 2026), Soleus Capital Management, L.P. increased its position in NRIX. The position peaked in Q2 2024 at 2.06M shares.

Which other funds hold NRIX?

Other major institutional holders of NRIX include Vestal Point Capital, LP, Deep Track Capital, LP, Rubric Capital Management LP, among 46 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.